Dividend Investing Center
Portfolio Strategy Center
ETFs & Funds
should start getting a lot of serious attention going into 11/29 PDUFA cabozantinib. Priority review.. $
Add a reply...
Latest StockTalks »
people get EXEL breaking news and analysis by email alert.
Get email alerts on EXEL »
Get latest price
From other sites
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
at Zacks.com (Tue, 4:50PM)
Exelixis's Cabozantinib Granted Priority Review in the U.S.
at Zacks.com (Jan 29, 2016)
Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
at Zacks.com (Nov 26, 2015)
Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf
at Zacks.com (Nov 23, 2015)
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
at Zacks.com (Nov 11, 2015)